BridgeBio Oncology Therapeutics (BBOT) updates CEO option grant terms

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. reported an update to its Chief Executive Officer and director’s stock option grant. On December 10, 2025, the company rescinded 1,114,400 stock options from an option grant originally dated October 2, 2025, as an exempt disposition to the issuer under Rule 16b-3.

After this change, 500,000 stock options from the original grant remain outstanding, each with an exercise price of $12.44 and an expiration date of October 1, 2035. The options vest in 48 substantially equal monthly installments beginning on the monthly anniversary of October 2, 2025, as long as the reporting person continues to provide service to the company on each vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wallace Eli M.

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.44	12/10/2025		D			1,114,400	(1)	10/01/2035	Common Stock	1,114,400	(2)	500,000	D

Explanation of Responses:

1. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 2, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

2. On December 10, 2025, the Issuer rescinded 1,114,400 stock options that were part of the Reporting Person's option grant dated October 2, 2025 (the "Rescinded Portion"). The Rescinded Portion was cancelled and the remaining 500,000 stock options from the original grant continue to remain outstanding. The rescission was an exempt disposition to the Issuer per Rule 16b-3.

	/s/ Aaron Chan, Attorney-in-Fact	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BridgeBio Oncology Therapeutics (BBOT) report?

The company reported that on December 10, 2025, it rescinded 1,114,400 stock options from a prior grant to a reporting person who serves as both a director and Chief Executive Officer. This was treated as an exempt disposition to the issuer under Rule 16b-3.

How many BridgeBio Oncology Therapeutics (BBOT) stock options remain after the rescission?

Following the rescission of 1,114,400 stock options, 500,000 stock options from the original October 2, 2025 grant continue to remain outstanding for the reporting person.

What are the key terms of the remaining BBOT stock options?

The remaining stock options have an exercise price of $12.44 per share and an expiration date of October 1, 2035. They relate to Common Stock of BridgeBio Oncology Therapeutics, Inc.

How do the vesting terms work for the BBOT stock options in this filing?

According to the disclosure, 1/48th of the shares subject to the option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 2, 2025, provided the reporting person continues to serve the company on each such date.

What SEC rule applies to the rescinded BridgeBio Oncology Therapeutics stock options?

The rescission of the 1,114,400 stock options was characterized as an exempt disposition to the issuer under Rule 16b-3, which governs certain insider transactions in equity securities.

Is the Form 4 for BBOT filed by one or multiple reporting persons?

The disclosure states that the Form 4 was filed by one reporting person, who is identified as both a director and an officer (Chief Executive Officer) of BridgeBio Oncology Therapeutics, Inc.